Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirukumab in anti-TNF refractory rheumatoid arthritis
NCT01606761Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2012
- Primary completion
- Mar 2015
- Modality
- Monoclonal Antibodies
- Countries
- 22
01
Overview
Phase 3, randomised, double-blind trial of sirukumab in rheumatoid arthritis (RA), sponsored by Janssen Pharmaceutical. Started Aug 2012; status: completed.
02
Drugs
sirukumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01606761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01606761.